Evidence map›Paper›PMID 29228659›Full record

ArticleOncotarget2017

Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: a Chinese Western Cooperative Gastrointestinal Oncology Group Study.

Qiu Li, Feng Wen, Chengya Zhou, Meng Qiu, Jiyan Liu, Jing Chen, Cheng Yi, Zhiping Li, Deyun Luo, Feng Xu and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Qiu Li *Department of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Feng Wen *Department of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Chengya Zhou *Oncology Department, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, P.R. China.
Meng QiuDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Jiyan LiuDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Jing ChenOncology Department, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, P.R. China.
Cheng YiDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Zhiping LiDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Deyun LuoDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Feng XuDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Xiaohong CaiOncology Department, Sichuan Cancer Hospital, Chengdu, 610041, Sichuan Province, P.R. China.
Feng BiDepartment of Medical Oncology, Laboratory of Signal Transduction and Molecular Targeting Therapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan Province, P.R. China.
Western Cooperative Gastrointestinal Oncology Group of China
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Until now, no standard chemotherapy has been widely accepted for advanced gastric cancer (GC). The current research aimed to compare folinic acid, fluorouracil with irinotecan (mFOLFIRI) or with oxaliplatin (mFOLFOX7) as first-line treatments in patients with locally advanced GC in an open, randomized, phase II study. Previously untreated metastatic or recurrent GC patients with measurable disease received mFOLFIRI (arm A) or mFOLFOX7 (arm B) every 2 weeks. The defined second-line treatment was mFOLFOX7 for arm A and mFOLFIRI for arm B. Primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS), disease control rate (DCR) and toxicity. The evaluable population consisted of 128 patients (54 in arm A; 74 in arm B). Median PFS of arm A was 2.9 months (m) (95% confidence interval,

Indexed as

gastric cancermFOLFIRImFOLFOX7

Identifiers

PMID29228659
PMCPMC5716699
OpenAlexW2624333167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.